Generic Name and Formulations:
Cefazolin (as sodium) 500mg/vial, 1g/vial; pwd for IM or IV inj or IV infusion after reconstitution and dilution; sodium content 48mg/g cefazolin.
Various generic manufacturers
Indications for Cefazolin:
Susceptible bacterial infections including septicemia, respiratory, biliary or GU tract, skin and skin structure, bone and joint, endocarditis. Surgical prophylaxis.
Pneumococcal pneumonia: 500mg every 12 hours. Mild infections: 250–500mg every 8 hours; moderate to severe infections: 500mg–1g every 6–8 hours. Severe, life-threatening infections (eg, endocarditis, septicemia): 1–1.5g every 6 hours; max 12g/day. UTIs: 1g every 12 hours. Prophylaxis: see literature. Renal impairment (give initial loading dose): (CrCl 35–54mL/min): reduce dosing frequency to at least 8 hour intervals; (CrCl 11–34mL/min): reduce dose by 50%, give every 12 hours; (CrCl <10mL/min): reduce dose by 50%, give every 18–24 hours. Peritoneal dialysis: see literature.
<1 month: not recommended. ≥1 month: Mild to moderately severe infections: 25–50mg/kg per day in 3–4 divided doses. Severe infections: max 100mg/kg per day. Renal impairment (give initial loading dose): (CrCl 40–70mL/min): reduce dose by 40%; give every 12 hours; (CrCl 20–40mL/min): reduce dose by 75%, give every 12 hours; (CrCl 5–20mL/min): reduce dose by 90%, give every 24 hours.
Penicillin or other allergy. Renal impairment: reduce dose. GI disease (esp. colitis). Monitor PT in patients at risk (eg, renal or hepatic impairment, poor nutritional state, long term use, or anticoagulant therapy). Pregnancy (Cat.B). Nursing mothers.
Potentiated by probenecid. May cause false (+) Clinitest, Benedict's, or Fehling's soln.
GI upset, anaphylaxis, rash, pruritus, local reactions, blood dyscrasias, elevated liver enzymes.
Formerly known under the brand names Ancef, Kefzol.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC